deltatrials
Terminated EARLY_PHASE1 INTERVENTIONAL 2-arm NCT01479348

Imaging Study for FdCyd and THU Cancer Treatment

Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine

Sponsor: National Cancer Institute (NCI)

Conditions Breast Neoplasms Head and Neck Neoplasms Lung Neoplasms Urinary Bladder Neoplasms
Interventions Positron emission tomography (PET)/Computed tomography (CT) Tetrahydrouridine (oral) Tetrahydrouridine intravenous (IV) [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Updated 15 times since 2017 Last updated: May 21, 2020 Started: Nov 1, 2011 Primary completion: Aug 4, 2017 Completion: Jan 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow, insufficient accrual.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Breast Neoplasms trials with similar outcome

Browse all Breast Neoplasms trials

This EARLY_PHASE1 trial investigates Breast Neoplasms and Head and Neck Neoplasms and is currently terminated or withdrawn. National Cancer Institute (NCI) leads this study, which shows 15 recorded versions since 2011 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Aug 2017 · 6 months · monthly snapshot~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Jun 2020 · 16 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated EARLY_PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated EARLY_PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated EARLY_PHASE1

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated EARLY_PHASE1

▶ Show 10 earlier versions

  1. Jul 2020 — Jan 2021 [monthly]

    Terminated EARLY_PHASE1

  2. Jun 2020 — Jul 2020 [monthly]

    Terminated EARLY_PHASE1

  3. Feb 2019 — Jun 2020 [monthly]

    Terminated EARLY_PHASE1

    Status: Completed → Terminated

  4. Aug 2018 — Feb 2019 [monthly]

    Completed EARLY_PHASE1

  5. Jul 2018 — Aug 2018 [monthly]

    Completed EARLY_PHASE1

  6. Jun 2018 — Jul 2018 [monthly]

    Completed EARLY_PHASE1

  7. Mar 2018 — Jun 2018 [monthly]

    Completed EARLY_PHASE1

  8. Aug 2017 — Mar 2018 [monthly]

    Completed EARLY_PHASE1

    Status: Enrolling By Invitation → Completed

  9. Feb 2017 — Aug 2017 [monthly]

    Enrolling By Invitation EARLY_PHASE1

    Phase: Phase 0 → EARLY_PHASE1

  10. Jan 2017 — Feb 2017 [monthly]

    Enrolling By Invitation Phase 0

    First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations